Contents

Ackenheil, M., see Müller-Spahn, F., et al. 436

Ahlenius, S., Archer, T., Tandberg, B., Hillegaart, V.
Effect of (−)3-PPP on acquisition and retention of a conditioned avoidance response in the rat 441

Albus, M., see Müller-Spahn, F., et al. 436

Alfredsson, G., Härnryd, C., Wiesel, F.-A.
Effects of sulpiride and chlorpromazine on depressive symptoms in schizophrenic patients – relationship to drug concentrations 237

Allerup, P., see Bech, P., et al. 276

Altman, H. J., Nordy, D. A., Ögren, S. O.
Role of serotonin in memory: Facilitation by alaproclate and zimeldine 496

Amit, Z., see Blander, A., et al. 124

Amit, Z., see Socaransky, S. M., et al. 250

Angel, A., see Mason, S. T. 304

Ankier, S. I., see Brooks, D., et al. 1

Annable, L., see Chouinard, G. 282

Ansseau, M., Doumont, A., von Frenckell, R., Collard, J.
Duration of benzodiazepine clinical activity: Lack of direct relationship with plasma half-life. A comparison of single vs divided dosage schedules of prazepam 293

Apud, J., see Cuomo, V., et al. 287

Aragon, C. M. G., see Socaransky, S. M., et al. 250

Archer, T., Ögren, S.-O., Johansson, G., Ross, S. B.
The effect of acute zimeldine and alaproclate administration on the acquisition of two-way active avoidance: Comparison with other anti-depressant agents, test of selectivity and sub-chronic studies 188

Archer, T., see Ahlenius, S., et al. 441

Arnt, J., Fredricson Overø, K., Hyttel, J., Olsen, R.
Changes in rat dopamine- and serotonin function in vivo after prolonged administration of the specific 5-HT uptake inhibitor, citalopram 457

Aston-Jones, S., Aston-Jones, G., Koob, G. F.
Cocaine antagonizes anxiolytic effects of ethanol 28

Aston-Jones, G., see Aston-Jones, S., et al. 28

Averbuch, I., see Stein, D., et al. 566

Balduini, W., see Lombardelli, G., et al. 285

Bannet, J., see Stein, D., et al. 566

Barkai, A. I., Kowalik, S., Reches, A.
Dopamine and serotonin metabolites in rat cerebroventricular fluid following withdrawal of haloperidol or electroshock treatment 352

Baumann, P., Gaillard, J.-M., Jonzier-Perey, M., Gerber, C., Bouras, C.
Evaluation of the levels of free and total amitriptyline and metabolites in the plasma and brain of the rat after long-term administration of doses used in receptor studies 489

Bavli, S., see Lex, B. W., et al. 178

Beaton, J. M., see Liu, W.-F., et al. 486

Bech, P., Allerup, P., Reisby, N., Gram, L. F.
Assessment of symptom change from improvement curves on the Hamilton depression scale in trials with antidepressants 276

Beirness, D., Vogel-Sprott, M.
Alcohol tolerance in social drinkers: Operant and classical conditioning effects 393

Beirness, D., Vogel-Sprott, M.
The development of alcohol tolerance: Acute recovery as a predictor 398

Belmaker, R. H., see Stein, D., et al. 566

Ben-Horin, N., Ben-Horin, E., Frenk, H.
The effects of proglumide on morphine induced motility changes 541

Ben-Horin, E., see Ben-Horin, N., et al. 541

Berchou, R., see Pomara, N., et al. 342

Bigelow, G. E., see Griffiths, R. R., et al. 147

Bigleow, G. E., see Stitzer, M. L., et al. 402

Blair, R., see Blander, A., et al. 124

Blander, A., Hunt, T., Blair, R., Amit, Z.
Conditioned place preference: An evaluation of morphine's positive reinforcing properties 124

Blander, A., see Socaransky, S. M., et al. 250

Blier, P., de Montigny, C., Tardif, D.
Effects of the two antidepressant drugs mianserin and indalpine on the serotonergic system: Single-cell studies in the rat 242

Block, R., see Pomara, N., et al. 342

Bloom, F. E., see Pettit, H. O., et al. 167

Bose, R., Pinsky, C.
Central depressant action of cesium in mice 80

Bouras, C., see Baumann, P., et al. 489

Bouras, N., see Brooks, D., et al. 1

Bowers Jr., M. B., Hoffman Jr., F. J.
Homovanillic acid in rat caudate and prefrontal cortex following phencyclidine and amphetamine 136

Bradshaw, C. M., see Morley, M. J., et al. 531

Bradshaw, C. M., see Ruddle, H. V., et al. 520

Branconnier, R. J., Oxenkrug, G. F., McIntyre, I., Pomara, N., Harto, N. E., Gershon, S.
Prediction of serum cortisol response to dexamethasone in normal volunteers: A multivariate approach 274

Bridges, P. K., see Brooks, D., et al. 1

Brooks, D., Prothero, W., Bouras, N., Bridges, P. K., Jarman, C. M. B., Ankier, S. I.
Trazodone – a comparison of single night-time and divided daily dosage regimens 1

Buckman, M. T., see Lisansky, J., et al. 331

Cagiano, R., see Cuomo, V., et al. 287

Carroll, M. E., Stotz, D. C.
Increased phencyclidine self-administration due to food deprivation: Interaction with concentration and training conditions 299

Casey, D. E., see Noring, U., et al. 569

Cattabeni, F., see Lombardelli, G., et al. 285

Chazan, S., see Stein, D., et al. 566

Cheal, M.
Differential effects of haloperidol and clozapine on attention 268

Chouinard, G., Annable, L.
An early Phase II clinical trial of BW234U in the treatment of acute schizophrenia in newly admitted patients 282

Christen, P., see Ortmann, R., et al. 22

Clarke, P. B. S., Kumar, R.
Effects of nicotine and *d*-amphetamine on intracranial self-stimulation in a shuttle box test in rats 109

Cohen, B. M., see Zubenko, G. S. 289

Collard, J., see Ansseau, M., et al. 293

Colle, L. M., see Wise, R. A. 446

Cooper, S. J., Gilbert, D. B.
Naloxone suppresses fluid consumption in tests of choice between sodium chloride solutions and water in male and female water-deprived rats 362

Cooper, S. J., see Dourish, C. T. 132

Coward, D. M.
Modification of nigral kainic acid-induced ipsilateral circling behaviour in the rat by neuroleptics and by contralateral caudate ablation 526

Cuomo, V., Cagiano, R., Apud, J., Masotto, C., Racagni, G.
Behavioural responsiveness to muscimol and apomorphine 2 months after prolonged treatment with estradiol in rats 287

Davis, J. M., see Rubinstein-Kawamoto, J., et al. 155

De Montigny, C., see Blier, P., et al. 242

DeVane, C. L., Simpkins, J. W., Stout, S. A.
Cerebral and blood pharmacokinetics of imipramine and its active metabolites in the pregnant rat 225

De Vane, C. L., see Stout, S. A. 39

Devoize, J.-L., Rigal, F., Eschalier, A., Trolese, J.-F., Renoux, M.
Influence of naloxone on antidepressant drug effects in the forced swimming test in mice 71

Domino, E. F., see Kovacic, B. 310

Doumont, A., see Ansseau, M., et al. 293

Dourish, C. T., Cooper, S. J.
Environmental experience produces qualitative changes in the stimulant effects of β-phenylethylamine in rats 132

Dyr, W., see Kostowski, W., et al. 85

Ebert, M. H., see Martin, P. R., et al. 58

Elsner, J., see Looser, R., et al. 323

Eschalier, A., see Devoize, J.-L., et al. 71

Ettenberg, A., see Pettit, H. O., et al. 167

Fava, G. A., see Lisansky, J., et al. 331

Fava, M., see Lisansky, J., et al. 331

Feduzi, A., see Lombardelli, G., et al. 285

Felner, A., see Ortmann, R., et al. 22

Fenton, H. M., see Liebman, J. M., et al. 336

Feyerabend, C., see West, R. J., et al. 120

File, S. E., see Lister, R. G., et al. 420

Fleminger, S., see Rupniak, N. M. J., et al. 503

Ford, K. E., see Fowler, S. C., et al. 368

Fowler, S. C., Ford, K. E., Gramling, S. E., Nail, G. L.
Acute and subchronic effects of neuroleptics on quantitative measures of discriminative motor control in rats 368

Fredricson Overø, K., see Arnt, J., et al. 457

Frenk, H., see Ben-Horin, N., et al. 541

Gaillard, J.-M., see Baumann, P., et al. 489

Garcha, H. S., see Stolerman, I. P., et al. 413

Garver, D. L., Zemlan, F., Hirschowitz, J., Hitzemann, R., Mavroidis, M. L.
Dopamine and non-dopamine psychoses 138

Gelenberg, A. J., see Lamping, D. L., et al. 254

Gerber, C., see Baumann, P., et al. 489

Gerhardt, S., see Liebman, J. M., et al. 336

Gerlach, J., see Korsgaard, S., et al. 76

Gerlach, J., see Noring, U., et al. 569

Gershon, E. S., see Nurnberger Jr., J. I., et al. 200

Gershon, S., see Branconnier, R. J., et al. 274

Gershon, S., see Pomara, N., et al. 342

Ghoneim, M. M., see Hinrichs, J. V., et al. 158

Gilbert, D. B., see Cooper, S. J. 362

Glotzbach, R. K., see Preskorn, S. H., et al. 196

Goldstein, D. S., see Nurnberger Jr., J. I., et al. 200

Gordon, E. K., see Martin, P. R., et al. 58

Gram, L. F., see Bech, P., et al. 276

Gramling, S. E., see Fowler, S. C., et al. 368

Gray, J. A., see Tsaltas, E., et al. 549

Greenblatt, D. J., see Lister, R. G., et al. 420

Greenblatt, D. J., see Pomara, N., et al. 342

Greizerstein, H. B.
Ethanol and indomethacin interactions in motor impairment, hypnosis, and body temperature 101

Griffiths, R. R., McLeod, D. R., Bigelow, G. E., Liebson, I. A., Roache J. D.
Relative abuse liability of diazepam and oxazepam Behavioral and subjective dose effects 147

Grilly, D. M., Johnson, S. K., Minardo, R., Jacoby, D., LaRiccia, J.
How do tranquilizing agents selectivity inhibit conditioned avoidance responding? 262

Gugath, M., see Laakmann, G., et al. 66

Guido, J., see Pomara, N., et al. 342

Härnryd, C., see Alfredsson, G., et al. 237

Hall, M. D., see Rupniak, N. M. J., et al. 503, 512

Hall, N. R., see Liebman, J. M., et al. 336

Harto, N. E., see Branconnier, R. J., et al. 274

Harvey, K., see Lex, B. W., et al. 178

Hatsukami, D. K., Hughes, J. R., Pickens, R. W., Svikis, D.
Tobacco withdrawal symptoms: An experimental analysis 231

Hauksson, P., see Jakobsen, J., et al. 544

Herman, J. P., Stinus, L., LeMoal, M.
Repeated stress increases locomotor response to amphetamine 431

Hillegaart, V., see Ahlenius, S., et al. 441

Hinrichs, J. V., Ghoneim, M. M., Mewaldt, S. P.
Diazepam and memory: Retrograde facilitation produced by interference reduction 158

Hinrichs, J. V., see Hughes, L. M., et al. 318

Hirschowitz, J., see Garver, D. L., et al. 138

Hitzemann, R., see Garver, D. L., et al. 138

Ho, I. K., see Sivam, S. P. 64

Hoffman Jr., F. J., see Bowers, Jr., M. B. 136

Holingsworth, E. B., Patrick, G. A.
Sedation produced by prostaglandins is not a nonspecific fatty acid effect 423

Hollander, E., see Nurnberger Jr., J. I., et al. 200

Hu, N.-W., see Liu, W.-F., et al. 486

Hughes, L. M., Wasserman, E. A., Hinrichs, J. V.
Chronic diazepam administration and appetitive discrimination learning: Acquisition versus steady-state performance in pigeons 318

Hughes, J. R., see Hatsukami, D. K., et al. 231

Hunt, T., see Blander, A., et al. 124

Hyttel, J., see Arnt, J., et al. 457

Idemudia, S. O., McMillan, D. E.
Effects of *d*-amphetamine on spontaneous motor activity in pigeons 315

Irwin, G. H., see Preskorn, S. H., et al. 196

Iwamoto, E. T.
An assessment of the spontaneous activity of rats administered morphine, phencyclidine, or nicotine using automated and observational methods 374

Jackson, H. C., Sewell, R. D. E.
The involvement of μ- and κ- but not δ-opioid receptors in the body weight gain of suckling rats 143

Jacoby, D., see Grilly, D. M., et al. 262

Jakobsen, J., Hauksson, P., Vestergaard, P.
Heart rate variation in patients treated with antidepressants. An index of anticholinergic effects? 544

Jarman, C. M. B., see Brooks, D., et al. 1

Jarvis, M. J., see West, R. J., et al. 120, 141

Jenner, P., see Rupniak, N. M. J., et al. 503, 512

Jeste, D. V., Stoff, D. M., Rawlings, R., Wyatt, R. J.
Pharmacogenetics of phenylethylamine: Determination of heritability and genetic transmission of locomotor effects in recombinant inbred strains of mice 537

Jimerson, S., see Nurnberger Jr., J. I., et al. 200

Johansson, G., see Archer, T., et al. 188

Johnson, S. K., see Grilly, D. M., et al. 262

Jonzier-Perey, M., see Baumann, P., et al. 489

Juhl, R. P., see Smith, R. B., et al. 452

Juul Povlsen, U., see Noring, U., et al. 569

Kadam, B., see West, R. J., et al. 141

Kalant, H., see Stiglick, A., et al. 476

Kane, J. M., see Kinon, B. J., et al. 347

Katz, J. L., Valentino, R. J.
The opiate quasiwithdrawal syndrome in rhesus monkeys: Comparison of naloxone-precipitated withdrawal to effects of cholinergic agents 12

Keane, P. E., see Simiand, J., et al. 48

Kellner, R., see Lisansky, J., et al. 331

Kent, T. A., see Preskorn, S. H., et al. 196

Kessler, L., see Nurnberger Jr., J. I., et al. 200

Khazanie, P. G., see Madakasira, S., et al. 574

Kilpatrick, G., see Rupniak, N. M. J., et al. 503, 512

Kinon, B. J., Merson, D., Kane, J. M.
Effect of daily dose of chronic haloperidol and chronic apomorphine on behavioral hypersensitivity in the rat 347

Kloss, M. W., Rosen, G. M., Rauckman, E. J.
Biotransformation of norcocaine to norcocaine nitroxide by rat brain microsomes 221

Koek, W., Slangen, J. L.
Acute effects of naloxone and naltrexone, but lack of delayed effects, on exploratory behavior in the rat 383

Koller, W. C.
Effects of intermittent haloperidol treatment on dopamine receptor sensitivity in guinea pigs 98

Koob, G. F., see Aston-Jones, S., et al. 28

Koob, G. F., see Pettit, H. O., et al. 167

Koob, G. P., see Swerdlow, N. R. 163

Kopin, I. J., see Martin, P. R., et al. 58

Korsgaard, S., Noring, U., Gerlach, J.
Fluperlapine in tardive dyskinesia and parkinsonism 76

Kostowski, W., Dyr, W., Zacharski, B.
A study of the effects of clonidine on the EEG in rats treated with single and multiple doses of antidepressants 85

Kovacic, B., Domino, E. F.
Fluphenazine-induced acute and tardive dyskinesias in monkeys 310

Kowalik, S., see Barkai, A. I., et al. 352

Kroboth, P. D., see Smith, R. B., et al. 452

Kumar, R., see Clarke, P. B. S. 109

Kumar, R., see Stolerman, I. P., et al. 413

Kuno, H., see Shimizu, J., et al. 20

Kuruvilla, A., Uretsky, N. J.
Effect of intrastriatal administration of cholinergic and GABAergic agonists on apomorphine-induced circling 42

Laakmann, G., Wittmann, M., Gugath, M., Mueller, O. A., Treusch, J., Wahlster, U., Stalla, G. K.
Effects of psychotropic drugs (desimipramine, chlorimipramine, sulpiride and diazepam) on the human HPA axis 66

Lamping, D. L., Spring, B., Gelenberg, A. J.
Effects of two antidepressants on memory performance in depressed outpatients: A double-blind study 254

Landa, L., see Stein, D., et al. 566

LaRiccia, J., see Grilly, D. M., et al. 262

Lauber, J., see Ortmann, R., et al. 22

Lehmann, E., Lienert, G. A.
Differential improvements from haloperidol in two types of schizophrenics 96

LeMoal, M., see Herman, J. P., et al. 431

Lex, B. W., Mendelson, J. H., Bavli, S., Harvey, K., Mello, N. K.
Effects of acute marijuana smoking on pulse rate and mood states in women 178

Liebman, J. M., Hall, N. R., Prowse, J., Gerhardt, S., Noreika, L., Fenton, H. M.
Comparative effects of β_2-adrenoceptor agonists on intracranial self-stimulation, Sidman avoidance, and motor activity in rats 336

Liebson, I. A., see Griffiths, R. R., et al. 147

Liebson, I. A., see Stitzer, M. L., et al. 402

Lienert, G. A., see Lehmann, E. 96

Lisansky, J., Fava, G. A., Buckman, M. T., Kellner, R., Fava, M., Zielezny, M., Peake, G. T.
Prolactin, amitriptyline, and recovery from depression 331

Lister, R. G., Greenblatt, D. J., File, S. E.
A pharmacokinetic study of CGS-8216, a benzodiazepine receptor ligand, in the rat 420

Liu, W.-F., Hu, N.-W., Beaton, J. M.
Biphasic effects of 3-quinuclidinyl benzilate on spontaneous motor activity in mice 486

Llewellyn, M. E., see Stiglick, A., et al. 476

Loke, W. H., Meliska, C. J.
Effects of caffeine use and ingestion on a protracted visual vigilance task 54

Lombardelli, G., Balduini, W., Feduzi, A., Peruzzi, G., Cattabeni, F.
Long-lasting tolerance to stimulatory effects of perinatal caffeine treatment 285

Looser, R., Elsner, J., Zbinden, G.
Behavioral effects of cyclazocine on rats assessed in the open field and residential maze 323

Madakasira, S., Khazanie, P. G., Sato, T. L.
Single-dose single-point method in amitriptyline therapy 574

Malmgren, R.
Platelets and biogenic amines. 1. Platelets are poor investigative models for dopamine re-uptake 480

Mann, S., see Rupniak, N. M. J., et al. 503

Marsden, C. D., see Rupniak, N. M. J., et al. 503, 512

Martin, P. R., Ebert, M. H., Gordon, E. K., Weingartner, H., Kopin, I. J.
Catecholamine metabolism during clonidine withdrawal 58

Mason, S. T., Angel, A.
Chronic and acute administration of typical and atypical antidepressants on activity of brain noradrenaline systems in the rat thiopentone anaesthesia model 304

Masotto, C., see Cuomo, V., et al. 287

Masters, D. B., see Wagner, G. C., et al. 32

Mavroidis, M. L., see Garver, D. L., et al. 138

May, G., see Müller-Spahn, F., et al. 436

McCaul, M. E., see Stitzer, M. L., et al. 402

McIntyre, I., see Branconnier, R. J., et al. 274

McLeod, D. R., see Griffiths, R. R., et al. 147

McMillan, D. E., see Idemudia, S. O. 315

Meliska, C. J., see Loke, W. H. 54

Mello, N. K., see Lex, B. W., et al. 178

Mendelson, J. H., see Lex, B. W., et al. 178

Merson, D., see Kinon, B. J., et al. 347

Mewaldt, S. P., see Hinrichs, J. V., et al. 158

Minardo, R., see Grilly, D. M., et al. 262

Morley, M. J., Bradshaw, C. M., Szabadi, E.
The effect of pimozide on variable-interval performance: A test of the 'anhedonia' hypothesis of the mode of action of neuroleptics 531

Morley, M. J., see Ruddle, H. V., et al. 520

Morre, M., see Simiand, J., et al. 48

Mueller, O. A., see Laakmann, G., et al. 66

Müller-Spahn, F., Ackenheil, M., Albus, M., May, G., Naber, D., Welter, D., Zander, K.
Neuroendocrine effects of apomorphine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal Relations to psychopathology and tardive dyskinesia 436

Naber, D., see Müller-Spahn, F., et al. 436

Nadi, N. S., see Nurnberger Jr., J. I., et al. 200

Nail, G. L., see Fowler, S. C., et al. 368

Nakazawa, T., see Shimizu, J., et al. 20

Newton, R. E., see Pomara, N., et al. 342

Niesink, R. J. M., see van Ree, J. M., et al. 561

Nir, I., Veldhuis, H. D., van Ree, J. M.
Δ^1-Tetrahydrocannabinol-induced circling behavior in rats: A possible measured of psychotomimetic activity? 556

Nir, I., see van Ree, J. M., et al. 561

Nomura, S., see Shimizu, J., et al. 20

Nordy, D. A., see Altman, H. J., et al. 496

Noreika, L., see Liebman, J. M., et al. 336

Noring, U., Juul Povlsen, U., Casey, D. E., Gerlach, J.
Effect of a cholinomimetric drug (RS 86) in tardive dyskinesia and drug-related parkinsonism 569

Noring, U., see Korsgaard, S., et al. 76

Nurnberger Jr., J. I., Simmons-Alling, S., Kessler, L., Jimerson, S., Schreiber, J., Hollander, E., Tamminga, C. A., Nadi, N. S., Goldstein, D. S., Gershon, E. S.
Separate mechanisms for behavioral, cardiovascular, and hormonal responses to dextroamphetamine in man 200

Ögren, S. O., see Altman, H. J., et al. 496

Ögren, S.-O., see Archer, T., et al. 188

Olsen, R., see Arnt, J., et al. 457

Ortmann, R., Schaub, M., Felner, A., Lauber, J., Christen, P., Waldmeier, P. C.
Phenylethylamine-induced stereotypies in the rat: a behavioral test system for assessment of MAO-B inhibitors 22

Overstreet, D., see Pilotto, R., et al. 174

Oxenkrug, G. F., see Branconnier, R. J., et al. 274

Pandey, G. N., see Rubinstein-Kawamoto, J., et al. 155

Patrick, G. A., see Holingsworth, E. B. 423

Peake, G. T., see Lisansky, J., et al. 331

Peeke, S. C., Peeke, H. V. S.
Attention, memory, and cigarette smoking 205

Peeke, H. V. S., see Peeke, S. C. 205

Peruzzi, G., see Lombardelli, G., et al. 285

Pettit, H. O., Ettenberg, A., Bloom, F. E., Koob, G. F.
Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats 167

Phillips, J. P., see Smith, R. B., et al. 452

Pickens, R. W., see Hatsukami, D. K., et al. 231

Pilotto, R., Singer, G., Overstreet, D.
Self-injection of diazepam in naive rats: Effects of dose, schedule and blockade of different receptors 174

Pinsky, C., see Bose, R. 80

Pizzey, T., see West, R. J., et al. 141

Pomara, N., Stanley, B., Block, R., Guido, J., Russ, D., Berchou, R., Stanley, M., Greenblatt, D. J., Newton, R. E., Gershon, S.
Adverse effects of single therapeutic doses of diazepam on performance in normal geriatric subjects: Relationship to plasma concentrations 342

Pomara, N., see Branconnier, R. J., et al. 274

Pratt, J. A., see Stolerman, I. P., et al. 413

Preskorn, S. H., Kent, T. A., Glotzbach, R. K., Irwin, G. H., Solnick, J. V.
Cerebromicrocirculatory defects in animal model of depression 196

Preston, G. C., see Tsaltas, E., et al. 549

Prothero, W., see Brooks, D., et al. 1

Prowse, J., see Liebman, J. M., et al. 336

Racagni, G., see Cuomo, V., et al. 287

Rauckman, E. J., see Kloss, M. W., et al. 221

Rawlings, R., see Jeste, D. V., et al. 537

Rawlins, J. N. P., see Tsaltas, E., et al. 549

Reches, A., see Barkai, A. I., et al. 352

Reisby, N., see Bech, P., et al. 276

Renoux, M., see Devoize, J.-L., et al. 71

Revell, A., see Wesnes, K. 5

Rigal, F., see Devoize, J.-L., et al. 71

Roache, J. D., see Griffiths, R. R., et al. 147

Robbins, T. W., see Taylor, J. R. 405

Robinson, T. E.
Behavioral sensitization: Characterization of enduring changes in rotational behavior produced by intermittent injections of amphetamine in male and female rats 466

Robinson, H. E., see Severson, J. A., et al. 115

Romano, J. A., Shih, T.-M.
The effect of adrenalectomy and dexamethasone on the antinociceptive effects of physostigmine 426

Rosen, G. M., see Kloss, M. W., et al. 221

Ross, S. B., see Archer, T., et al. 188

Rubin, E. H., Wooten, G. F.
The behavioral and biochemical effects of lithium on dopaminergic agonist-induced supersensitivity 217

Rubinstein-Kawamoto, J., Davis, J. M., Pandey, G. N.
Effects of antidepressants on the uptake and release of norepinephrine from rat cerebral cortex 155

Ruddle, H. V., Morley, M. J., Bradshaw, C. M., Szabadi, E.
The effect of pentobarbitone on variable-interval performance: Analysis in terms of Herrnstein's equation 520

Rupniak, N. M. J., Kilpatrick, G., Hall, M. D., Jenner, P., Marsden, C. D.
Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats 512

Rupniak, N. M. J., Mann, S., Hall, M. D., Fleminger, S., Kilpatrick, G., Jenner, P., Marsden, C. D.
Differential effects of continuous administration for 1 year of haloperidol or sulpiride on striatal dopamine function in the rat 503

Russ, D., see Pomara, N., et al. 342

Russell, M. A. H., see West, R. J., et al. 120, 141

Sanger, D. J.
Chlordiazepoxide-induced hyperphagia in rats: Lack of effect of GABA agonists and antagonists 388

Sato, T. L., see Madakasira, S., et al. 574

Schaub, M., see Ortmann, R., et al. 22

Schreiber, R. A., Ungar, A. L.
Glucose protects DBA/2J mice from audiogenic seizures: Correlation with brain glycogen levels 128

Schreiber, J., see Nurnberger Jr., J. I., et al. 200

Severson, J. A., Robinson, H. E., Simpson, G. M.
Neuroleptic-induced striatal dopamine receptor supersensitivity in mice: Relationship to dose and drug 115

Sewell, R. D. E., see Jackson, H. C. 141

Shih, T.-M., see Romano, J. A. 426

Shimizu, J., Nomura, S., Kuno, H., Nakazawa, T.
Effects of water temperature and weight of wheel load on water wheel turning behavior of imipramine administered mice 20

Simiand, J., Keane, P. E., Morre, M.
The staircase test in mice: A simple and efficient procedure for primary screening of anxiolytic agents 48

Simmons-Alling, S., see Nurnberger Jr., J. I., et al. 200

Simpkins, J. W., see DeVane, C. L., et al. 225

Simpson, G. M., see Severson, J. A., et al. 115

Singer, G., see Pilotto, R., et al. 174

Sivam, S. P., Ho, I. K.
Analgesic cross-tolerance between morphine and opioid peptides 64

Slangen, J. L., see Koek, W. 383

Smith, R. B., Kroboth, P. D., Vanderlugt, J. T., Phillips, J. P., Juhl, R. P.
Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration 452

Socaransky, S. M., Aragon, C. M. G., Amit, Z., Blander, A.
Higher correlation of ethanol consumption with brain than liver aldehyde dehydrogenase in three strains of rats 250

Solnick, J. V., see Preskorn, S. H., et al. 196

Spiegel, R., see Wettstein, A. 572

Spoerlein, M T., see Wilmot, C. A., et al. 105

Spring, B., see Lamping, D. L., et al. 254

Stalla, G. K., see Laakmann, G., et al. 66

Stanley, B., see Pomara, N., et al. 342

Stanley, M., see Pomara, N., et al. 342

Stein, D., Bannet, J., Averbuch, I., Landa, L., Chazan, S., Belmaker, R. H.
Ineffectiveness of vasopressin in the treatment of memory impairment in chronic schizophrenia 566

Stephens, K. R., see Young, A. M. 356

Stiglick, A., Llewellyn, M. E., Kalant, H.
Residual effects of prolonged cannabis tretment on shuttle-box avoidance in the rat 476

Stinus, L., see Herman, J. P., et al. 431

Stitzer, M. L., McCaul, M. E., Bigleow, G. E., Liebson, I. A.
Hydromorphone effects on human conversational speech 402

Stoff, D. M., see Jeste, D. V., et al. 537

Stolerman, I. P., Garcha, H. S., Pratt, J. A., Kumar, R.
Role of training dose in discrimination of nicotine and related compounds by rats 413

Stotz, D. C., see Carroll, M. E. 299

Stout, S. A., De Vane, C. L.
Quantification of imipramine and its major metabolites in whole blood, brain, and other tissues of the rat by liquid chromatography 39

Stout, S. A., see DeVane, C. L., et al. 225

Svikis, D., see Hatsukami, D. K., et al. 231

Swerdlow, N. R., Koob, G. P
Restrained rats learn amphetamine-conditioned locomotion, but not place preference 163

Szabadi, E., see Morley, M. J., et al. 531

Szabadi, E., see Ruddle, H. V., et al. 520

Tamminga, C. A., see Nurnberger Jr., J. I., et al. 200

Tandberg, B., see Ahlenius, S., et al. 441

Tardif, D., see Blier, P., et al. 242

Taylor, J. R., Robbins, T. W.
Enhanced behavioural control by conditioned reinforcers following microinjections of *d*-amphetamine into the nucleus accumbens 405

Tomie, A., see Wagner, G. C., et al. 32

Treusch, J., see Laakmann, G., et al. 66

Trolese, J.-F., see Devoize, J.-L., et al. 71

Trulson, M. E.
Effects of diazepam on behavior and dopamine-containing substantia nigra units in freely moving cats 91

Tsaltas, E., Preston, G. C., Rawlins, J. N. P., Winocur, G., Gray, J. A.
Dorsal bundle lesions do not affect latent inhibition of conditioned suppression 549

Ungar, A. L., see Schreiber, R. A. 128

Uretsky, N. J., see Kuruvilla, A. 42

Valentino, R. J., see Katz, J. L. 12

Vanderlugt, J. T., see Smith, R. B., et al. 452

VanderWende, C., see Wilmot, C. A., et al. 105

Van Ree, J. M., Niesink, R. J. M., Nir, I.
Δ^1-Tetrahydrocannabinol but not cannabidiol reduces contact and aggressive behavior of rats tested in dyadic encounters 561

Van Ree, J. M., see Nir, I., et al. 556

Veldhuis, H. D., see Nir, I., et al. 556

Vestergaard, P., see Jakobsen, J., et al. 544

Vogel-Sprott, M., see Beirness, D. 393

Vogel-Sprott, M., see Beirness, D. 398

Von Frenckell, R., see Ansseau, M., et al. 293

Wagner, G. C., Masters, D. B., Tomie, A.
Effects of phencyclidine, haloperidol, and naloxone on fixed-interval performance in rats 32

Wahlster, U., see Laakmann, G., et al. 66

Waldmeier, P. C., see Ortmann, R., et al. 22

Wasserman, E. A., see Hughes, L. M., et al. 318

Weingartner, H., see Martin, P. R., et al. 58

Welter, D., see Müller-Spahn, F., et al. 436

Wesnes, K., Revell, A.
The separate and combined effects of scopolamine and nicotine on human information processing 5

West, R. J., Russell, M. A. H., Jarvis, M. J., Feyerabend, C.
Does switching to an ultra-low nicotine cigarette induce nicotine withdrawal effects? 120

West, R. J., Russell, M. A. H., Jarvis, M. J., Pizzey, T., Kadam, B.
Urinary adrenaline concentrations during 10 days of smoking abstinence 141

Wettstein, A., Spiegel, R.
Clinical trials with the cholinergic drug RS 86 in Alzheimer's disease (AD) and senile dementia of the Alzheimer type (SDAT) 572

Wiesel, F.-A., see Alfredsson, G., et al. 237

Wilmot, C. A., VanderWende, C., Spoerlein, M. T.
Behavioral responses to apomorphine and amphetamine in differentially housed mice 105

Winocur, G., see Tsaltas, E., et al. 549

Wise, R. A., Colle, L. M.
Pimozide attenuates free feeding: Best scores analysis reveals a motivational deficit 446

Witkin, J. M.
Effects of some volatile sedative-hypnotics on punished behavior 16

Wittmann, M., see Laakmann, G., et al. 66

Wooten, G. F., see Rubin, E. H. 217

Wyatt, R. J., see Jeste, D. V., et al. 537

Young, A. M., Stephens, K. R.
Antagonism of the discriminative effects of ethylketazocine, cyclazocine, and nalorphine in macaques 356

Zacharski, B., see Kostowski, W., et al. 85

Zander, K., see Müller-Spahn, F., et al. 436

Zbinden, G., see Looser, R., et al. 323

Zemlan, F., see Garver, D. L., et al. 138

Zielezny, M., see Lisansky, J., et al. 331

Zubenko, G. S., Cohen, B. M.
In vitro effects of psychotropic agents on the microviscosity of platelet membranes 289

Indexed in Current Contents

Subject Index

A

Abuse liability 147
Acetaldehyde 250
Acetylcholine release 12
ACTH 66
Activity monitoring 374
Acute effects 178
Acute recovery 398
Adrenal axis 426
Adrenalectomy 426
Aged 342
Aging 274
Alaproclate 188, 496
Alcohol tolerance 393
Alprazolam 452
Alzheimer's disease 572
Amitryptiline 254, 331, 489
Amphetamine 105, 132, 163, 217, 432, 466, 537
d-Amphetamine 109, 136, 315, 405
Amphetamine aggregation mortility 80
Amphetamine psychosis 466
Anabasine 413
Anaesthesia 304
"Anhedonia"-hypothesis 531
Animal model 196
Anticholinergic effects 254, 544
Anticholinergics 486
Anticonvulsant 128
Antidepressant 457, 574
Antidepressant drugs 71, 242, 544
Antidepressants 48, 85, 188, 304
Antidepressants, atypical 155
Antidepressants, tricyclic 39, 155
Antiepileptics 48
Antinociception 426
Antipsychotic drug 138
Antipsychotic effects 76, 80
Anxiety 28, 54
Anxiety disorders 293
Anxiolytics 48
Apomorphine 105, 138, 268, 287, 347, 466
Assay 574
Ataxia 28
Attention 205
Avoidance 188, 336, 441

B

Behavior, stereotyped 20
Behavioral response 200
Benzodiazepine 174, 342, 420
Benzodiazepines 48, 293
Beta-Adrenoceptor 336
Beta-Phenylethylamine 132
Beta receptors 304
Bicuculline 174, 388
Biogenic amines 196
Body weight gain 141
Boredom 54
Brain 128, 420, 489
Brain aldehyde dehydrogenase 250
Brain stimulation reward 109
Buschke Selective Reminding Task 342

C

Caffeine 285
Caffeine ingestion 54
Cannabidiol 556, 561
Cats 91
Cebus apella 310
Cerebral blood flow 196
Cesium 80
Chloral hydrate 16
Chlordiazepoxide 368
Chlorimipramine 66
Chlorpromazine 237, 262, 368
Cholecystokinin 138, 541
Cholinergic pathways 5
Cholinesterase inhibitors 426
Cholinomimetics 569
Chromatography 38
Chronic administration 109
Chronic cannabis 476
Cigarette withdrawal 141
Circling behavior 556, 561
Citalopram 457
Clenbuterol 336
Climbing behavior 105
Clonidine 58, 85, 262
Clonidine-antidepressants interaction 85
Clovoxamine 254
Clozapine 115, 268, 368, 503
CNS drug modification 80
Cocaine 28, 167, 221
Concentration 299
Conditioned avoidance response 262
Conditioned reinforcement 405
Conditioning 466
Conditioning, operant classical 393
Cortisol 66
CSF 352
Cuadate nucleus 405
Cyclazocine 323
Cytisine 413

D

DA receptor activation 42
Depression 1, 196, 254, 331, 574
Depression rating 276
Depressive symptoms 237
Depth of processing 205
Desimipramine 38, 66, 225
Dexamethasone 426
Dexamethasone suppression test 274
Dextroamphetamine 200
Diazepam 16, 66, 91, 147, 158, 174, 262, 318, 342
Differential housing 105
Different improvements 96
Discrimination 318
Dopamine 91, 138, 167, 174, 217, 305, 331, 431, 466, 480
Dopamine autoreceptor 441
Dopamine metabolites 217, 352
Dopamine receptor 457, 503, 512
Dopamine receptors 98, 115, 352
Dorsal noradrenergic bundle 549
Dorsal raphe nucleus 242
Dosage regiments 1
Drinking behavior 250
Drug abuse 147
Drug abusers 402
Drug discrimination 352, 413
Drug holiday 98
Drug reinforcement 402
Drug response latency 138
Dyskinesia 310
Dystonia 310

E

EEG activity 85
Effect monitoring 276
Electroshock treatment 352
Energetic levels 86
Environmental experience 132
Escape 20, 262
Estradiol treatment 287
Ethanol 16, 28, 101
Ethchlorvynol 16
Ethylketazocine 357
Exploration 48, 383
Extrapyramidal symptoms 310

F

Feeding 446
Fixed-interval schedule 32
Fluorescence polarization 289
Fluperlapine 76
Food deprivation 299
Food intake 388
Food reward 446
Food satiation 299
Force band 368
Force variance 368
Free radicals 221
Free recall 158

G

GABA 174, 388
Genetics 537
Gerbils 268
Glucose 124
Glycogen 128
Gonadal hormones 466
Growth hormone 138, 436
Guinea pigs 99

H

Habituation 268
Haloperidol 32, 96, 115, 174, 262, 347, 352, 368, 503, 512
Hamilton depression scale 276
Heart rate 178
Heart rate variation 544
Heritability 537
Hernstein's equation 520, 531
Heroin 167
Hippocampus 242
History 299
Homovanillic acid 136
5-HT-system 242
Humans 1, 15, 54, 58, 66, 76, 96, 120, 138, 141, 147, 158, 178, 200, 205, 237, 254, 282, 293, 331, 342, 393, 398, 402, 436, 452, 480, 544, 566, 569, 572, 576
Human speech 402
Hydromorphine 402
2-Hydroxydesimipramine 39, 225
2-Hydroxyimipramine 39, 225
5-Hydroxytryptamine 480
6-Hydroxydopamine 167, 466, 549
Hydroxylated metabolites 486
Hyperactivity 163
Hypermotility 457
Hypersensitivity 347

I

Imipramine 20, 38, 225, 480
Improved scores 276
Indalpine 242
Indomethacin 101
Inhibition 480
Interactions 101
Interference 158
Intoxication 178
Intracranial self-stimulation 109, 336
Investigation 268
Iprindole 304

K

Kainic acid 526
Kinetics 489

L

Latent inhibition 549
Learning 318
Lever pressing 32
Lithium 217
Locomotion 105, 163, 285, 323, 431, 537, 541
Locomotor activity 383

M

MAO-B-inhibitor 22
Marijuana 178
Mechanisms of action 200
Membrane fluidity 289
Memory 205, 254, 318, 342, 566
Memory facilitation 158
Memory, human 158
Memory retrieval 496
Menstrual cycle phases 178
Mescortical dopamine neurons 136
Metabolism 250
Metanephrine 58
Mianserin 242, 304
Mice 20, 48, 64, 71, 80, 105, 115, 128, 486, 537
Microviscosity 289
Molindone 115
Monkeys 12, 310, 357
Mood 54, 178
Morphine 64, 124, 262, 374, 541
Motor activity 80, 374, 486
Motor activity, spontaneous 315
Motor control 368
Motor performance 109
Muscarinic agonist 572
Muscarinic receptors 42, 426
Muscimol 287, 388

N

Nalorphine 357
Naloxone 12, 32, 71, 174, 362, 383
Naltrexone 357, 383
Neuroleptic 138, 446
Neuroleptic therapy, long-term 436
Neuroleptics 48, 98, 268, 368, 526, 531
Neuropeptides 138
Neurotoxicology 80
Nicotine 5, 109, 120, 205, 374, 413
Noradrenaline 304, 549
Norepinephrine 147, 155
Norepinephrine release 155
Norepinephrine uptake 155
Normetanephrine 58
Nucleus accumbens 167, 405

O

Operant behavior 318, 520, 531
Opiate 167
Opiate agonists 12
Opiate dependence 12
Opiate drugs 402
Opiates 64, 124, 362
Opiates, endogenous 426
Opioid peptides 64
Opioid receptors 141
Oxazepam 147
Oxotremorine 413

P

Parkinsonism 76, 569
Passive avoidance 496
PCA 188
PCP 299
Pentobarbital hypnosis 80

Pentobarbitone 512
Perinatal treatment 285
Pharmacokinetics 225, 420, 452
Phencyclidine 32, 135, 299, 374
Phenothiazines 289
Phenylethylamine 537
Physostigmine 12, 426
Picrotoxin 388
Pigeon 315, 318
Pimozide 268, 446, 531
Pituitary 426
Place preference 124, 163
Plasma 420, 489, 489
Plasma concentration 452
Plasma concentrations 342
Plasma neuroleptic levels 282
Plasma pharmacokinetics 293
Platelet membrane 289
Platelets 480
Prazepam 293
Prediction 574
Primates 310
Progabide 388
Proglumide 541
Prolactin 282, 331, 436
Psychomotor effects 147, 452
Psychomotor performance 342
Psychomotor stimulant 167
Psychopathology 436
Punishment 16

R

Rats 16, 22, 28, 32, 39, 42, 85, 101, 109, 124, 132, 136, 143, 155, 163, 167, 174, 188, 196, 217, 221, 225, 231, 242, 250, 262, 274, 285, 287, 304, 323, 336, 347, 352, 362, 368, 374, 383, 388, 405, 413, 420, 426, 431, 441, 446, 457, 466, 489, 496, 503, 512, 520, 526, 541, 549, 556, 561
Rearing 48
Receptor sensitivity 38
Recognition 158
Reinforcement 124, 167
Relative potency 147
Residential maze 323
Response initiation 446
Response strength 262
Retrograde enhancement 158
Reverse tolerance 466
Rotation 556, 561
Rotational behavior 466

S

Salbutamol 336
Saline consumption 362
Schizophrenia 237, 282, 537, 566
Schizophrenics 96
Schizophrenics, chronic 436
Scopolamine 5
Screening 48
Screening Test for Antidepressants 20
Selective attention 268, 549
Selectivity 188
Self-administration 167
Sensitization 242, 466
Serotonin 304, 331, 496
Serotonin receptor 457
Serum cortisol 274
Sex 362
Sex differences 466
Shuttle box 109
Shuttle-box avoidance 476
Signal detection 254
Single dose 574
Sleep 1
Sleeping time 304
Smoking 205, 231
Smoking history 178
Social interactions 561
Sodium preference 352
Steady state 574
Stereotypy 512
Stress 431
Striatal function 42
Striatum 115, 503
Stroop test 5
Subchronic administration 188
Subjective effects 147
Subsensitivity 242
Substantia nigra 91, 526
Suckling rats 143
Sulpiride 66, 237, 503, 512
Superfusion 155
Superoxide 221
Supersensitivity 115, 217, 503
Swimming Test 71

T

Tail flick 426
Tardive dyskinesia 76, 98, 310, 347, 436, 569
Terbutaline 336
Tetrabenazine 196
Thalamus 405
Thiopentone 304
Thioridazine 115
Time course 147
Tissue-drug concentration 39
Tobacco 231
Tolerance 64, 109, 147, 285
Toxicology 81
Training condition 299
Trazodone 1
Tremor 368
Tricyclic antidepressants 254

U

Unit activity 91
Uptake 480
Urinary adrenaline 141

V

Variability 574
Vasopressin 566
Vigilance 54

W

Withdrawal 12, 58
Withdrawal effects 120

Z

Zimeldine 188, 496
Zimelidine 304